Search

EHA-SWG Scientific Meeting on From aging hematopoietic stem cells to age-related diseases: opportunities for intervention Page

Dates: November 13-15, 2025
Location: Barcelona, Spain
Chairs: M Essers, E Laurenti, S Valletta, K Kirschner
Collaborating SWG: EHA Specialized Working Group (SWG) on Stem Cells and SWG on Aging

Registration will be open soon

Join leading experts in hematopoietic stem cell (HSC) biology and aging, and…

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

Meeting program

Thursday, April 18*All times are in EET. 16:00 - 19:00 EET Satellite symposia

Novartis
Hoffman-La Roche
Takeda
Various satellite symposia will take place the day before the meeting for national and regional participants.

Read more

EU Calls for proposal 2021

Introduction
Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.

Read more

HARMONY: Innovative Medicines Initiative approves € 40 million project for better care of patients with hematologic malignancies

HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS)…

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Message from the EHA President

As the year closes, is with great pleasure that I reflect on 2021, six months into my Presidency of the European Hematology Association (EHA). It is also time to look forward to the new year.

Read more